The SS-A/Ro 60 kDa test is a chemiluminescent immunoassay (CLIA), for use on IDS automated analyzers. It is used for the quantitative determination of the specific IgG antibodies directed against protein SS-A/Ro 60 kDa in human samples of serum or plasma (EDTA-K3, Heparin-Na or Sodium Citrate).

The extractable nuclear anti-antigen (ENA) autoantibodies represent a large family of non-organ- and non- species-specific autoantibodies, detection of which is of great importance in laboratory diagnosis of systemic rheumatic autoimmune diseases. (1,2,3,4)

Anti SS-A/Ro autoantibodies are the most common of those detected during screening for systemic rheumatic diseases.

The SS-A/Ro antigen is composed of a particle of RNA rich in uridine bonded to a 60 kDa protein(5); another 52 kDa protein participates in the complex via a protein-protein interaction(6).

Anti SS-A/Ro autoantibodies are class IgG polyclonal antibodies that recognise conformational epitopes on the 60 kDa molecule and, to a lesser degree, on the 52 kDa molecule. Half of the anti-SS-A/Ro sera contain direct antibodies against the two components, the remaining half has autoantibodies directed against only one of the two antigens.

Anti-SS-A/Ro 60 kDa antigens are prevalently found in individuals suffering from Sjiogren Syndrome (SS) and in those with systemic lupus erythematosus (SLE)(7). Anti-SS-A/Ro 52 kDa antigens too are commonly found in individuals suffering from SS and from SLE, but unlike the anti-SS-A/Ro 60 kDa antigens, they are also found in patients suffering from systemic sclerosis (8) and with polymyositis and dermatomyositis (8,9). Moreover, anti-SS-A/Ro 52 kDa have been found, but less frequently, in patients suffering from biliary cirrhosis(10) and those suffering with type 1 autoimmune hepatitis(11).

  1. CA von Mühlen, EM Tan. Autoantibodies in the diagnosis of systemic rheumatic diseases. Sem Arthr Rheum 1995; 24: 323-58.
  1. RL Humbel. Auto-immunité, auto-anticorps et maladie. In : Humbel RL, ed. Autoanticorps et maladies autoimmunes, Paris, France : Edition Scientifiques Elsevier; 1997: 17-20.
  1. PN Hollingsworth, SC Pummer, RL Dawkins. Antinuclear antibodies. In : Peter JB, Shoenfeld Y, eds. Autoantibodies. Amsterdam, The Netherlands : Elsevier Science BV; 1996: 74-90.
  1. CA Slater, RB Davis, RH Shmerling. Antinuclear antibodies testing. A study of clinical utility. Arch Int Med 1996; 156: 1421-5.
  1. PJ Venables, PR Smith, RN Maini. Purification and characterization of the Sjögren’s syndrome A and B antigens. Clin Exp Immunol 1983; 54: 731-8.
  1. E Ben-Chetrit, EKL Chan, KF Sullivan, EM Tan. A 52-kD protein is a novel component of the antigenic particle. J Exp Med 1988;167:1560-71.
  1. E Ben-Chetrit, R Fox, EM Tan. Dissociation of immune responses to the SS-A/Ro(Ro) 52-kD and 60-kD polypeptides in systemic lupus erythematosus and Sjögren’s syndrome. Arthr Rheum 1990; 33: 349-55.
  1. Frank MB, McCubbin V, Trieu E,Wu Y, Isenber DA, Targoff In. The association of anti-Ro 52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 12: 137-142, 1999.
  1. Rutjes SA, Vree WT Egberts, Jongen P, Van Den Hoogen F, Pruijn GJ, Van Venrooij WJ. Anti-Ro 52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic myopathy. Clin Exp Immunol 109: 32-40, 1997.
  1. Granito A, Muratori P, Muratori L et al. Antibodies to 52kDa and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol. Ther 26(6), 831-838 ( 2007 ).
  1. Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro/SS-A/Ro and soluble liver antigen in type 1 autoimmune hepatitis. Liver International 32 ( 1): 85-92 ( 2012 ).